Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics

Glioblastoma (GBM) is the most common and aggressive intracranial malignant brain tumor, and the abnormal expression of HDAC1 is closely correlated to the progression, recurrence and metastasis of GBM cells, making selective inhibition of HDAC1 a promising strategy for GBM treatments. Among all avai...

Full description

Bibliographic Details
Main Authors: Yang Zhang, Tingting Fu, Yuxiang Ren, Fengcheng Li, Guoxun Zheng, Jiajun Hong, Xiaojun Yao, Weiwei Xue, Feng Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fmolb.2020.00041/full
id doaj-6b0334fc733c4af1af355b3d8451aa63
record_format Article
spelling doaj-6b0334fc733c4af1af355b3d8451aa632020-11-25T02:57:57ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2020-03-01710.3389/fmolb.2020.00041513391Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular DynamicsYang Zhang0Yang Zhang1Tingting Fu2Yuxiang Ren3Fengcheng Li4Guoxun Zheng5Jiajun Hong6Xiaojun Yao7Weiwei Xue8Feng Zhu9Feng Zhu10College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaSchool of Pharmaceutical Sciences, Chongqing University, Chongqing, ChinaSchool of Pharmaceutical Sciences, Chongqing University, Chongqing, ChinaCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaSchool of Pharmaceutical Sciences, Chongqing University, Chongqing, ChinaCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaState Key Laboratory of Applied Organic Chemistry and Department of Chemistry, Lanzhou University, Lanzhou, ChinaSchool of Pharmaceutical Sciences, Chongqing University, Chongqing, ChinaCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, ChinaSchool of Pharmaceutical Sciences, Chongqing University, Chongqing, ChinaGlioblastoma (GBM) is the most common and aggressive intracranial malignant brain tumor, and the abnormal expression of HDAC1 is closely correlated to the progression, recurrence and metastasis of GBM cells, making selective inhibition of HDAC1 a promising strategy for GBM treatments. Among all available selective HDAC1 inhibitors, the macrocyclic peptides have gained great attention due to their remarkable inhibitory selectivity on HDAC1. However, the binding mechanism underlying this selectivity is still elusive, which increases the difficulty of designing and synthesizing the macrocyclic peptide-based anti-GBM drug. Herein, multiple computational approaches were employed to explore the binding behaviors of a typical macrocyclic peptide FK228 in both HDAC1 and HDAC6. Starting from the docking conformations of FK228 in the binding pockets of HDAC1&6, relatively long MD simulation (500 ns) shown that the hydrophobic interaction and hydrogen bonding of E91 and D92 in the Loop2 of HDAC1 with the Cap had a certain traction effect on FK228, and the sub-pocket formed by Loop1 and Loop2 in HDAC1 could better accommodate the Cap group, which had a positive effect on maintaining the active conformation of FK228. While the weakening of the interactions between FK228 and the residues in the Loop2 of HDAC6 during the MD simulation led to the large deflection of FK228 in the binding site, which also resulted in the decrease in the interactions between the Linker region of FK228 and the previously identified key amino acids (H134, F143, H174, and F203). Therefore, the residues located in Loop1 and Loop2 contributed in maintaining the active conformation of FK228, which would provide valuable hints for the discovery and design of novel macrocyclic polypeptide HDAC inhibitors.https://www.frontiersin.org/article/10.3389/fmolb.2020.00041/fullHDACmacrocyclic peptidesmolecular dockingMD simulationbinding free energiesinteraction fingerprints
collection DOAJ
language English
format Article
sources DOAJ
author Yang Zhang
Yang Zhang
Tingting Fu
Yuxiang Ren
Fengcheng Li
Guoxun Zheng
Jiajun Hong
Xiaojun Yao
Weiwei Xue
Feng Zhu
Feng Zhu
spellingShingle Yang Zhang
Yang Zhang
Tingting Fu
Yuxiang Ren
Fengcheng Li
Guoxun Zheng
Jiajun Hong
Xiaojun Yao
Weiwei Xue
Feng Zhu
Feng Zhu
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics
Frontiers in Molecular Biosciences
HDAC
macrocyclic peptides
molecular docking
MD simulation
binding free energies
interaction fingerprints
author_facet Yang Zhang
Yang Zhang
Tingting Fu
Yuxiang Ren
Fengcheng Li
Guoxun Zheng
Jiajun Hong
Xiaojun Yao
Weiwei Xue
Feng Zhu
Feng Zhu
author_sort Yang Zhang
title Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics
title_short Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics
title_full Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics
title_fullStr Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics
title_full_unstemmed Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics
title_sort selective inhibition of hdac1 by macrocyclic polypeptide for the treatment of glioblastoma: a binding mechanistic analysis based on molecular dynamics
publisher Frontiers Media S.A.
series Frontiers in Molecular Biosciences
issn 2296-889X
publishDate 2020-03-01
description Glioblastoma (GBM) is the most common and aggressive intracranial malignant brain tumor, and the abnormal expression of HDAC1 is closely correlated to the progression, recurrence and metastasis of GBM cells, making selective inhibition of HDAC1 a promising strategy for GBM treatments. Among all available selective HDAC1 inhibitors, the macrocyclic peptides have gained great attention due to their remarkable inhibitory selectivity on HDAC1. However, the binding mechanism underlying this selectivity is still elusive, which increases the difficulty of designing and synthesizing the macrocyclic peptide-based anti-GBM drug. Herein, multiple computational approaches were employed to explore the binding behaviors of a typical macrocyclic peptide FK228 in both HDAC1 and HDAC6. Starting from the docking conformations of FK228 in the binding pockets of HDAC1&6, relatively long MD simulation (500 ns) shown that the hydrophobic interaction and hydrogen bonding of E91 and D92 in the Loop2 of HDAC1 with the Cap had a certain traction effect on FK228, and the sub-pocket formed by Loop1 and Loop2 in HDAC1 could better accommodate the Cap group, which had a positive effect on maintaining the active conformation of FK228. While the weakening of the interactions between FK228 and the residues in the Loop2 of HDAC6 during the MD simulation led to the large deflection of FK228 in the binding site, which also resulted in the decrease in the interactions between the Linker region of FK228 and the previously identified key amino acids (H134, F143, H174, and F203). Therefore, the residues located in Loop1 and Loop2 contributed in maintaining the active conformation of FK228, which would provide valuable hints for the discovery and design of novel macrocyclic polypeptide HDAC inhibitors.
topic HDAC
macrocyclic peptides
molecular docking
MD simulation
binding free energies
interaction fingerprints
url https://www.frontiersin.org/article/10.3389/fmolb.2020.00041/full
work_keys_str_mv AT yangzhang selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT yangzhang selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT tingtingfu selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT yuxiangren selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT fengchengli selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT guoxunzheng selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT jiajunhong selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT xiaojunyao selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT weiweixue selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT fengzhu selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
AT fengzhu selectiveinhibitionofhdac1bymacrocyclicpolypeptideforthetreatmentofglioblastomaabindingmechanisticanalysisbasedonmoleculardynamics
_version_ 1724709217319780352